Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Express Scripts
Colorcon
Baxter
Medtronic

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

MINIPRESS XL Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Minipress Xl patents expire, and when can generic versions of Minipress Xl launch?

Minipress Xl is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in MINIPRESS XL is prazosin hydrochloride. There are seventeen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.

Drug patent expirations by year for MINIPRESS XL
Recent Clinical Trials for MINIPRESS XL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Colorado, DenverPhase 4
University of ManitobaPhase 1
National Institute on Aging (NIA)Phase 2

See all MINIPRESS XL clinical trials

Recent Litigation for MINIPRESS XL

Identify potential future generic entrants

District Court Litigation
Case NameDate
Purdue Pharma L.P. v. PAR Pharmaceutical, Inc.2013-05-17
Endo Pharmaceuticals Inc., and Grunenthal GbmH v. Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc.2012-11-05
Purdue Pharma LP v. Sandoz Inc.2012-10-10

See all MINIPRESS XL litigation

Synonyms for MINIPRESS XL
(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(furan-2-yl)methanone hydrochloride
[4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-2-furanylmethanone Hydrochloride
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone hydrochloride
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone;hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonxyl)piperazine Hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine monohydrochloride
19237-84-4
19237-84-4,19216-56-9(freebase)
2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline hydrochloride
2-[4-(furan-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxychinazolin-4-aminhydrochlorid
4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone, chloride
4-Amino-6,7-dimethoxy-2-[4-(2-furoyl)piperazine-1-yl]quinazoline hydrochloride
86126-06-9
AB0013242
AB2000097
AC-699
AC1L29YV
AC1Q5KOO
Adversuten
Adverszuten
AF-0012
AKOS015895394
Alpress LP
AOB5346
API0003916
BBC/839
BC205115
BCP13643
BG0291
C19H21N5O4.HCl
CC-33905
CCG-39227
CHEBI:8365
CHEMBL1558
CP-12,299-1
CP-12299-1
CP-122991
CS-2089
CTK3J2335
D00609
Deprazolin
DTXSID50172822
EINECS 242-903-4
EU-0101002
Furazosin hydrochloride
GP4454
H37P844
H764
HMS1570N16
HMS1920J10
HSDB
HY-B0193A
Hypovase
Hypovasole
I06-0650
KS-00000ZMQ
LP01002
LS-140003
MCULE-7492026178
Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-2-furanyl-, hydrochloride (1:1)
MFCD00058177
Minipress
Minipress (TN)
Minipress,Vasoflex,Pressin and Hypovase
MLS000028454
MLS001148201
MLS001333696
MLS002153280
MLS002222304
MolPort-001-684-488
NCGC00094296-01
NCGC00094296-02
NCGC00094296-03
NCGC00094296-04
NCGC00094296-05
NCGC00261687-01
NSC 292810
NSC-292810
NSC-757286
NSC292810
NSC757286
Opera_ID_370
P0938
Peripress
Pharmakon1600-01500495
piperazin-1-yl)(furan-2-yl)
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-, monohydrochloride
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-, monohydrochloride
Piperazine,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-, monohydrochloride
Piperazine,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-, monohydrochloride
Pratsiol
Prazosin (hydrochloride)
Prazosin clorhidrato [Spanish]
Prazosin HCl
Prazosin HCl (Furazosin HCl)
Prazosin hydrochloride
Prazosin hydrochloride (JP17/USP)
Prazosin hydrochloride [USAN:JAN]
Prazosin hydrochloride [USAN:USP:JAN]
Prazosin hydrochloride, >=99% (TLC)
Prazosin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Prazosin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Prazosin hydrochloride;
prazosine hydrochloride
Pressin and Hypovase
PubChem19837
Quinazoline, 4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-, hydrochloride
RTR-008931
s1424
SB17352
SCHEMBL41257
Sinetens
SMR000058384
SPECTRUM1500495
SR-01000003052
SR-01000003052-2
SR-01000003052-8
ST057530
SYN3017
TL8001578
Tox21_501002
TR-008931
UNII-X0Z7454B90
VA11573
Vasoflex
W-107719
WFXFYZULCQKPIP-UHFFFAOYSA-N
X0Z7454B90
ZX-AS005038

US Patents and Regulatory Information for MINIPRESS XL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-001 Jan 29, 1992 DISCN No No   Start Trial   Start Trial   Start Trial
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-002 Jan 29, 1992 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MINIPRESS XL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-002 Jan 29, 1992   Start Trial   Start Trial
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-001 Jan 29, 1992   Start Trial   Start Trial
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-001 Jan 29, 1992   Start Trial   Start Trial
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-001 Jan 29, 1992   Start Trial   Start Trial
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-002 Jan 29, 1992   Start Trial   Start Trial
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-002 Jan 29, 1992   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Dow
Boehringer Ingelheim
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.